Use this identifier to quote or link this document: http://hdl.handle.net/2072/223892

Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.
Llovet i Bayer, Josep Maria; Mas, X.; Aponte, John J.; Fuster Obregón, Josep; Navasa Anadón, Miguel A.; Christensen, E.; Rodés, J.; Bruix Tudó, Jordi
2014-02-18
Trasplantament hepàtic
Anàlisi cost-benefici
Càncer de fetge
Hepatic transplantation
Cost effectiveness
Liver cancer
(c) BMJ Publishing Group Ltd and British Society of Gastroenterology, 2002
Article
BMJ Group
         

Show full item record

Related documents

Other documents of the same author

Llovet i Bayer, Josep Maria; Mas, X.; Aponte, John J.; Fuster Obregón, Josep; Navasa, Miquel; Christensen, E.; Rodés, J.; Bruix Tudó, Jordi
Neuberger, J.; Christensen, E.; Portmann, B.; Caballeria Rovira, Joan; Rodés, J.; Ranek, L.; Tygstrup, Niels; Williams, Roger
Zhu, Andrew X.; Rosmorduc, Olivier; Evans, T.R. Jeffry; Ross, Paul J.; Santoro, Armando; Carrilho, Flair Jose; Bruix Tudó, Jordi; Qin, Shukui; Thuluvath, Paul J.; Llovet i Bayer, Josep Maria; Leberre, Marie-Aude; Jensen, Markus; Meinhardt, Gerold; Kang, Yoon-Koo
Villanueva, Augusto; Portela, Anna; Sayols, Sergi; Battiston, Carlo; Hoshida, Yujin; Méndez-González, Jesús; Imbeaud, Sandrine; Letouzé, Eric; Hernandez-Gea, Virginia; Cornella, Helena; Pinyol, Roser; Solé Arqués, Manuel; Fuster Obregón, Josep; Zucman-Rossi, Jessica; Mazzaferro, Vincenzo; Esteller, Manel; Llovet i Bayer, Josep Maria; HEPTROMIC Consortium
 

Coordination

 

Supporters